Evidence map›Paper›PMID 39433719›Full record

ArticleAnnals of surgical oncology2025

Enhancing Preoperative Diagnosis Accuracy of Stage III Gastric Cancer with Circulating circRNAs.

Koichi Matsutoka, Katsutoshi Shoda, Yudai Higuchi, Takashi Nakayama, Ryo Saito, Suguru Maruyama, Koichi Takiguchi, Yuki Nakata, Shinji Furuya, Kensuke Shiraishi and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Koichi MatsutokaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Katsutoshi ShodaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan. kshoda@yamanashi.ac.jp.
Yudai HiguchiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Takashi NakayamaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Ryo SaitoFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Suguru MaruyamaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Koichi TakiguchiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Yuki NakataFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Shinji FuruyaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Kensuke ShiraishiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Yoshihiko KawaguchiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Hidetake AmemiyaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Kiyoshi MasudaKawasaki Medical School, Okayama, Japan.
Daisuke IchikawaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis remains poor for stage III gastric cancer, and neoadjuvant chemotherapy is increasingly used to improve outcomes. Accurate diagnosis prior to treatment is essential to develop appropriate treatment strategies for poor prognosis subgroups. This study aims to enhance the accuracy of pre-treatment gastric cancer diagnosis using a biological approach centered on circulating circular RNA (circRNA). MATERIALS AND

methodsWe conducted a comprehensive analysis of circRNA expression profiles using two Gene Expression Omnibus datasets to identify circRNA candidates associated with stage III gastric cancer. Subsequently, we validated these circRNA biomarkers in two independent clinical cohorts comprising a total of 174 patients with gastric cancer and non-disease controls through real-time polymerase chain reaction (PCR).

resultsGenome-wide circRNA analysis identified a panel of four biomarkers capable of diagnosing pathologically confirmed stage III (pStage III) gastric cancer. In a training cohort (n = 83), a clinically applicable panel of four circRNAs was developed (AUC 0.81), which was successfully validated in an independent clinical cohort (n = 82; AUC 0.76). To assess clinical utility, we combined clinical imaging (cStage) with the circRNA panel. Among those initially diagnosed as cStage III but later confirmed as pStage I/II, 86% were accurately diagnosed using the molecular biological approach with circRNAs.

conclusionsWe have developed a circRNA-based non-invasive liquid biopsy that can improve the diagnostic performance of pStage III gastric cancer before treatment. Our circRNA model could provide a sophisticated and personalized approach to assist in treatment planning for patients with advanced gastric cancer.

Indexed as

Biomarkers, TumorNeoplasm StagingRNA, CircularStomach NeoplasmsAgedCase-Control StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPreoperative CarePrognosisBiomarkers, TumorRNA, CircularCircular RNAClinical stageGastric cancerLiquid biopsyNeoadjuvant treatment

Identifiers

PMID39433719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.